2022 World Conference on Lung Cancer (ePosters)-EP08.02-029. Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

Pdf Summary

Sunvozertinib (DZD9008) is an oral inhibitor designed to target EGFR Exon20 insertion mutations (Exon20ins) in non-small cell lung cancer (NSCLC) patients. In earlier clinical studies, sunvozertinib exhibited significant anti-tumor activity, leading to its Breakthrough Therapy Designation by the US FDA and China NMPA. Currently, it is being studied as a second-line treatment after platinum-containing chemotherapies and a first-line treatment for treatment-naïve patients. <br /><br />The updated results from multicenter studies (WU-KONG1, WU-KONG2, and WU-KONG6) demonstrate that sunvozertinib has superior clinical efficacy in advanced NSCLC with EGFR Exon20ins after platinum-based chemotherapy. The overall response rate (ORR) at a dose of 300 mg once daily was 52.4%. It also showed significant response in patients with baseline brain metastasis, with an ORR of 44% in this subgroup. Sunvozertinib exhibited clinical activity across a broad range of EGFR Exon20ins mutation subtypes and regardless of mutation positions.<br /><br />Safety analysis indicated that sunvozertinib has a benign safety profile comparable to other EGFR tyrosine kinase inhibitors (TKIs). The most common drug-related adverse events were diarrhea and rash, mostly at mild or moderate grades.<br /><br />The study included a total of 119 evaluable platinum-pretreated NSCLC patients with EGFR Exon20ins in the efficacy set. In the safety set, there were 238 evaluable patients. Patient demographics showed a median age of 57.5 years, with a majority of female patients. The study also included patients with prior systemic anti-cancer treatment and baseline brain metastasis.<br /><br />Overall, sunvozertinib represents a promising treatment option for NSCLC patients with EGFR Exon20ins mutations, showing superior clinical efficacy, a favorable safety profile, and activity across various mutation subtypes. Further studies and development of sunvozertinib are ongoing, with the potential to provide a new treatment option for a subset of NSCLC patients.

Asset Subtitle

James Chih-Hsin Yang

Meta Tag

Speaker James Chih-Hsin Yang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Sunvozertinib

EGFR Exon20 insertion mutations

NSCLC

Breakthrough Therapy Designation

platinum-containing chemotherapies

clinical efficacy

baseline brain metastasis

safety profile

mutation subtypes

treatment option